BlackRock Health Sciences Term Trust (NYSE:BMEZ) Stock Price Down 1.2% – Time to Sell?

BlackRock Health Sciences Term Trust (NYSE:BMEZ)’s stock price fell 1.2% during mid-day trading on Thursday . The company traded as low as $16.50 and last traded at $16.5420. 103,693 shares changed hands during trading, a decline of 51% from the average session volume of 210,301 shares. The stock had previously closed at $16.75.

BlackRock Health Sciences Term Trust Price Performance

The stock has a 50-day moving average of $16.05 and a 200-day moving average of $14.99.

Institutional Trading of BlackRock Health Sciences Term Trust

A number of hedge funds and other institutional investors have recently made changes to their positions in BMEZ. Integrated Wealth Concepts LLC bought a new stake in shares of BlackRock Health Sciences Term Trust in the second quarter worth $46,000. Brown Lisle Cummings Inc. increased its stake in BlackRock Health Sciences Term Trust by 7.8% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 57,026 shares of the company’s stock valued at $875,000 after buying an additional 4,108 shares during the last quarter. Corient Private Wealth LP acquired a new stake in BlackRock Health Sciences Term Trust in the 2nd quarter valued at $467,000. Rivernorth Capital Management LLC lifted its position in BlackRock Health Sciences Term Trust by 24.8% during the 1st quarter. Rivernorth Capital Management LLC now owns 809,196 shares of the company’s stock worth $11,620,000 after buying an additional 160,629 shares in the last quarter. Finally, Saba Capital Management L.P. bought a new stake in BlackRock Health Sciences Term Trust during the 1st quarter worth about $10,907,000.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.